<div id="readability-page-1"><p>ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) shot up 3.5% on Wednesday after Deutsche Bank Aktiengesellschaft raised their price target on the stock to $35.00. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. ACADIA Pharmaceuticals traded as high as $22.75 and last traded at $22.44. 376,453 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 2,372,912 shares. The stock had previously closed at $21.69.</p><div><p><span></span><span>Get <strong>ACADIA Pharmaceuticals</strong> alerts:</span></p></div><ul><li>Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves</li></ul><p>Other analysts have also recently issued research reports about the stock. Cantor Fitzgerald  reaffirmed an &#34;overweight&#34; rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Royal Bank of Canada  reaffirmed an &#34;outperform&#34; rating and issued a $26.00 price target on shares of ACADIA Pharmaceuticals in a research report on Monday. BMO Capital Markets raised their price target on shares of ACADIA Pharmaceuticals from $24.00 to $28.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday. Oppenheimer  reiterated a &#34;market perform&#34; rating on shares of ACADIA Pharmaceuticals in a research note on Friday. Finally, HC Wainwright lifted their price objective on shares of ACADIA Pharmaceuticals from $27.00 to $32.00 and gave the company a &#34;buy&#34; rating in a research note on Monday. Six research analysts have rated the stock with a hold rating and nine have assigned  a buy rating to the company. Based on data from MarketBeat.com, ACADIA Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $26.83.</p><p><b>Read Our Latest Stock Analysis on ACADIA Pharmaceuticals</b></p><h2>Insiders Place Their Bets</h2><p>In other news, EVP Mark C. Schneyer sold 3,171 shares of the company's stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $17.05, for a total transaction of $54,065.55. Following the completion of the transaction, the executive vice president now directly owns 56,889 shares of the company's stock, valued at approximately $969,957.45. This represents a 5.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the company's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total transaction of $89,673.37. Following the transaction, the director now directly owns 17,595 shares of the company's stock, valued at approximately $320,756.85. This trade represents a 21.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,994 shares of company stock valued at $453,131 over the last three months. Insiders own  26.50% of the company's stock. </p><h2>Institutional Investors Weigh In On ACADIA Pharmaceuticals</h2><p>Hedge funds and other institutional investors have recently bought and sold shares of the business. Exchange Traded Concepts LLC bought a new position in shares of  ACADIA Pharmaceuticals in the first quarter worth approximately $29,000.  Banque Transatlantique SA bought a new position in  ACADIA Pharmaceuticals during the first quarter valued at approximately $31,000.  Picton Mahoney Asset Management bought a new position in  ACADIA Pharmaceuticals during the first quarter valued at approximately $32,000.  Federated Hermes Inc. lifted its position in  ACADIA Pharmaceuticals by 231.5% during the first quarter. Federated Hermes Inc. now owns 2,317 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 1,618 shares during the period.  Finally, Virtus Fund Advisers LLC bought a new position in  ACADIA Pharmaceuticals during the fourth quarter valued at approximately $39,000. Hedge funds and other institutional investors own  96.71% of the company's stock. </p><h2>ACADIA Pharmaceuticals Price Performance</h2><p>The company has a market cap of $3.76 billion, a P/E ratio of 28.77 and a beta of 0.47. The stock's 50-day moving average is $16.11 and its two-hundred day moving average is $17.19. </p><p>ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.01. The company had revenue of $244.32 million for the quarter, compared to the consensus estimate of $239.32 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The firm's revenue for the quarter was up 18.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 earnings per share.  On average, analysts predict that  ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current year. </p><h2>ACADIA Pharmaceuticals Company Profile</h2> (Get Free Report)<p>ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than ACADIA Pharmaceuticals</li><li>How to buy stock: A step-by-step guide for beginners </li><li>Rivian Stock Below $20: Charging Up or in the Breakdown Lane?</li><li>How to Use Stock Screeners to Find Stocks</li><li>Best Utilities Stocks for Stability and Growth in 2025</li><li>The 3 Best Fintech Stocks to Buy Now</li><li>Qualcomm’s Re-Entry Into the CPU Market May Not Be Enough</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in ACADIA Pharmaceuticals Right Now?</h2><p>Before you consider ACADIA Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.</p><p>While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ACAD

<p>ACADIA Pharmaceuticals (NASDAQ:ACAD) shares rose 3.5% after Deutsche Bank upgraded its price target to $35.00, maintaining a buy rating. The stock traded at $22.44, with a significant drop in trading volume. Other analysts also issued positive ratings, with price targets ranging from $26.00 to $32.00. Insiders have sold shares recently, and institutional investors hold 96.71% of the stock. The company reported a quarterly EPS of $0.11, exceeding estimates, with revenue up 18.7% year-over-year.</p>

ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Up 3.5% After Analyst Upgrade